
EquitySector - HealthcareVery High Risk
Direct
NAV (08-Sep-26)
Returns (Since Inception)
Fund Size
₹1,444 Cr
Expense Ratio
1.28%
ISIN
INF789F01TO9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
01 Jan 2013
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+18.94%
+17.59% (Cat Avg.)
3 Years
+24.67%
+20.86% (Cat Avg.)
5 Years
+16.42%
+14.15% (Cat Avg.)
10 Years
+14.71%
+14.61% (Cat Avg.)
Since Inception
+16.67%
— (Cat Avg.)
| Equity | ₹1,360.86 Cr | 94.27% |
| Others | ₹82.71 Cr | 5.73% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹119.09 Cr | 8.25% |
| Divi's Laboratories Ltd | Equity | ₹89.66 Cr | 6.21% |
| Net Current Assets | Cash | ₹82.41 Cr | 5.71% |
| Ajanta Pharma Ltd | Equity | ₹68.44 Cr | 4.74% |
| Gland Pharma Ltd | Equity | ₹53.39 Cr | 3.70% |
| Dr Reddy's Laboratories Ltd | Equity | ₹52.31 Cr | 3.62% |
| Alkem Laboratories Ltd | Equity | ₹47.43 Cr | 3.29% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹47.16 Cr | 3.27% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹44.81 Cr | 3.10% |
| Lupin Ltd | Equity | ₹44.61 Cr | 3.09% |
| Caplin Point Laboratories Ltd | Equity | ₹44.01 Cr | 3.05% |
| Ipca Laboratories Ltd | Equity | ₹41.48 Cr | 2.87% |
| Global Health Ltd | Equity | ₹40.59 Cr | 2.81% |
| Anthem Biosciences Ltd | Equity | ₹37.81 Cr | 2.62% |
| Fortis Healthcare Ltd | Equity | ₹34.01 Cr | 2.36% |
| Rainbow Childrens Medicare Ltd | Equity | ₹32.54 Cr | 2.25% |
| Marksans Pharma Ltd | Equity | ₹32.16 Cr | 2.23% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹32.13 Cr | 2.23% |
| Cohance Lifesciences Ltd | Equity | ₹31.92 Cr | 2.21% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹31.33 Cr | 2.17% |
| Aurobindo Pharma Ltd | Equity | ₹30.37 Cr | 2.10% |
| Procter & Gamble Health Ltd | Equity | ₹28.84 Cr | 2.00% |
| Aster DM Quality Care Ltd Ordinary Shares | Equity | ₹27.22 Cr | 1.89% |
| Sai Life Sciences Ltd | Equity | ₹25.9 Cr | 1.79% |
| Dr. Lal PathLabs Ltd | Equity | ₹23.25 Cr | 1.61% |
| Metropolis Healthcare Ltd | Equity | ₹22.53 Cr | 1.56% |
| Viyash Scientific Ltd | Equity | ₹22.19 Cr | 1.54% |
| Cipla Ltd | Equity | ₹21.14 Cr | 1.46% |
| Sudeep Pharma Ltd | Equity | ₹20.56 Cr | 1.42% |
| Biocon Ltd | Equity | ₹20.52 Cr | 1.42% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹20.09 Cr | 1.39% |
| Windlas Biotech Ltd | Equity | ₹18.53 Cr | 1.28% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹17.51 Cr | 1.21% |
| Alembic Pharmaceuticals Ltd | Equity | ₹16.7 Cr | 1.16% |
| Manipal Health Enterprises Ltd | Equity | ₹16.21 Cr | 1.12% |
| Pfizer Ltd | Equity | ₹16.08 Cr | 1.11% |
| Blue Jet Healthcare Ltd | Equity | ₹14.3 Cr | 0.99% |
| Laxmi Dental Ltd | Equity | ₹14.22 Cr | 0.98% |
| Emcure Pharmaceuticals Ltd | Equity | ₹12.85 Cr | 0.89% |
| Aarti Pharmalabs Ltd | Equity | ₹12.68 Cr | 0.88% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹10.01 Cr | 0.69% |
| Orchid Pharma Ltd | Equity | ₹9.85 Cr | 0.68% |
| Jubilant Pharmova Ltd | Equity | ₹7.91 Cr | 0.55% |
| Syngene International Ltd | Equity | ₹6.54 Cr | 0.45% |
| Short Term Deposits - | Cash - Collateral | ₹0.3 Cr | 0.02% |
Large Cap Stocks
19.19%
Mid Cap Stocks
33.33%
Small Cap Stocks
40.63%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,360.86 Cr | 94.27% |
Standard Deviation
This fund
15.93%
Cat. avg.
16.08%
Lower the better
Sharpe Ratio
This fund
1.11
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.63
Higher the better
Since May 2022
ISIN INF789F01TO9 | Expense Ratio 1.28% | Exit Load 1.00% | Fund Size ₹1,444 Cr | Age 13 years 8 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹3,66,598 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments